Take­da wa­gers $300M on Pro­tag­o­nist’s PhI­II rare dis­ease drug

Take­da is lend­ing Pro­tag­o­nist Ther­a­peu­tics a hand in steer­ing its lead rare dis­ease drug to mar­ket, buy­ing in­to its late-stage de­vel­op­ment and pend­ing com­mer­cial­iza­tion for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER